Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib
Leukemia, Published online: 11 June 2026; doi:10.1038/s41375-026-03002-4Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and ni



